Bioresorbable Orthopedic Implant, MAGNEZIX

  • Home
  • Blog
  • Bioresorbable Orthopedic Implant, MAGNEZIX

Syntellix Lauded by Frost & Sullivan for Breakthrough Technology in the Orthopedic and Trauma Market with its Bioresorbable Orthopedic Implant, MAGNEZIX

Syntellix Lauded by Frost & Sullivan for Breakthrough Technology in the Orthopedic and Trauma Market with its Bioresorbable Orthopedic Implant, MAGNEZIX

Based on its recent analysis of the European orthopedic and trauma market, Frost & Sullivan recognizes Syntellix AG with the 2020 European Entrepreneurial Company of the Year Award. Its MAGNEZIX products are the world's first magnesium-based, metallically stable bioresorbable orthopedic implants that are CE marked. The implants function similar to conventional steel or titanium devices but without the need for subsequent removal because it is absorbed by the body and replaced by new bone.

"The MAGNEZIX implant's unique capability of converting metal to bone makes it an ideal implant of the future," said Dr. Bejoy Daniel, senior industry analyst. "MAGNEZIX significantly reduces patient risks associated with hospitalization and surgery when using titanium implants, such as allergic or toxic reactions, possible cancer formation, hospital-acquired infection (HAI), or even COVID-19 transmission."

A major advantage of MAGNEZIX over existing resorbable polymer materials is its higher strength and excellent biocompatibility with a predictable degradation course, making it the right choice for a wide range of medical applications that require safe temporary fixation. MAGNEZIX implants are used for medical indications such as intra and extra articular fractures, bony avulsion of ligaments and tendons, and even in cases of osteochondral fractures and flakes. Moreover, the underlying material technology offers enormous potential benefits for better patient care in other medical fields, such as neurosurgery and dental implantology.

MAGNEZIX has an elasticity that is similar to human bone and thus leads to a relief of the bone that prevents the negative stress shielding effect as well as osteopenia. In general, pain perception for patients is greatly reduced. The MAGNEZIX implant offers surgeons ease of application and delivers reliable temporary fixation and stabilization. Additional features include metallic stability, full bio-absorbability, and osteoconductivity; these features, along with outstanding tolerability and anti-infectious properties, give it a significant competitive advantage.

"Healthcare authorities around the world have approved MAGNEZIX implants, and the FDA recently designated MAGNEZIX CS 3.2 as a 'Breakthrough Device', a privilege accorded to fewer than 1 percent of devices in the orthopedic field," noted Daniel. "Its unique benefits and materials make MAGNEZIX an ideal solution for use in medical applications and beyond."

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in devising a strong growth strategy and robustly implementing it. The recipient has shown strength in terms of innovation in products and technologies, leadership in customer value, as well as speed in response to market needs. The award looks at the emerging market players in the industry and recognizes their best practices that are positioned for future growth excellence.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

(LONDON, Dec. 8, 2020 /PRNewswire/Source: Frost & Sullivan)



You May Also Like

Zimmer Biomet Names CEO of Dental/Spine Spin-Off: Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that after an extensive search, Vafa Jamali has been appointed as CEO of "NewCo", the independent, publicly traded company that will be created by ... Read More

Bactiguard-coated Zimmer Biomet trauma implants receive European regulatory clearance: "I am very pleased that the CE mark has been secured for Bactiguard-coated Zimmer Biomet trauma implants. This clearance will pave the way for European market launch in 2021. At the same time, we are preparing for the submission of the U.S regulatory file ... Read More

A new non-surgical treatment to lessen patient’s pain and get them back to their active lifestyles: Miller Orthopedic Specialists introduces MOS Regenerative Medicine Solutions, a non-surgical treatment that uses a patient’s own stem cells to promote healing within. MOS Regenerative Medicine Solutions has multiple types of treatments that... Read More

Driving Orthopaedic Procedure Costs Down: OIC Launches One Procedure, One Price(TM) Initiative: In orthopaedic procedures, commoditized implants are typically the most significant expense. Medical devices companies have put exorbitant price tags on implants and tools differentiated by sales and marketing expenses, not innovative technology... Read More

Trauma Implants Market to Reach 10.14 Billion by 2026: The global Trauma Implants Market size is expected to reach USD 10.14 billion by 2026, exhibiting a CAGR of 4.3% during the forecast period. The increasing prevalence of sports injuries among children and teenagers will contribute significantly to the Trauma Implants Market share in the forthcoming years... Read More

The Coronavirus has increased the focus on healthcare and modern equipment: Globally, no sector has been placed under the magnifying glass more than the healthcare sector due to the Corona pandemic. Hospitals, outpatient clinics, practice-based physicians and care facilities have experienced a sudden increased demand for medical and laboratory technology... Read More

Video of the Week

Video helps you make a human connection with your viewers.